TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus

The clinical development of FtsZ-targeting benzamide compounds like PC190723 has been limited by poor drug-like and pharmacokinetic properties. Development of prodrugs of PC190723 (e.g., TXY541) resulted in enhanced pharmaceutical properties, which, in turn, led to improved intravenous efficacy as w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Main Authors: Kaul, Malvika, Mark, Lilly, Zhang, Yongzheng, Parhi, Ajit K., Lyu, Yi Lisa, Pawlak, Joan, Saravolatz, Stephanie, Saravolatz, Louis D., Weinstein, Melvin P., LaVoie, Edmond J., Pilch, Daniel S.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2015
Assuntos:
Pharmacology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4505295/
https://ncbi.nlm.nih.gov/pubmed/26033735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00708-15
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares